APS Support UK

For people with antiphospholipid syndrome



Colin Morrison, another kiltwalk, same big heart



Kevin Cloherty runs the Glasgow 10k



Lydia Goodall ran the London 10k in memory of her mum Elisabeth



Elli and Jamie Phillips run for 90 days

Annual Report 2025

Overview

Antiphospholipid syndrome (APS) is a potentially life-threatening autoimmune disease that causes the blood to clot too quickly.

APS can cause low-grade symptoms including headaches and migraines, memory problems, joint pain and fatigue. It can also trigger potentially fatal symptoms such as deep vein thrombosis (DVT), blood clots on the lung, strokes and heart attacks.

In pregnancy, APS is the most significant treatable cause of recurrent miscarriage and can increase the chance of stillbirth up to five times; it is also associated with other complications such as pre-eclampsia, low weight babies and premature births.

As of yet, we simply don't know why people develop APS, why some patients go on to have blood clots while others don't, why some women (but not all) have pregnancy problems and why some people are affected by symptoms more than others – vital research is needed before we can answer these questions.

However, we do know that being diagnosed as early as possible and treated correctly seems to have a direct bearing on how well people will feel in the future.

The national charity, APS Support UK, aims to achieve earlier diagnosis and offer support to anyone affected by APS through awareness, education and research.



Danny Lloyd, heroic catastrophic APS survivor



Kerri McNaught walks the West Highland Way

Introduction and Message from the Chair

We are pleased to present the APS Support UK Annual Report for 2025 and would like to extend our sincere thanks to everyone who has supported, contributed to and collaborated with the charity throughout the year.

We reached a significant milestone in 2025 by appointing the first-ever APS Clinical Nurse Specialist funded by APS Support UK. Following a robust bidding and recruitment process, we were delighted to appoint specialist haematology nurse Louise O'Prey to the role based at Leeds Teaching Hospitals NHS Trust in August this year. The APS CNS role is funded until at least August 2026, during which time, Louise will work towards developing nurse-led clinics for APS patients and producing educational resources for both patients and healthcare professionals. We are pleased to see this important initiative underway and look forward to its continued development.

Throughout 2025, we were also delighted to be able to continue funding research into antiphospholipid syndrome (APS) and were able to increase our maximum grant award from £10,000 to £20,000. This grant award increase attracted the highest number of applications received in the history of our APS Research Fund and we were thrilled to award five research grants. These worthy projects appear very exciting and we look forward to seeing how they develop and what their findings may contribute to our understanding of APS.

Patient involvement remains an important part of our contribution to research and we are grateful to our patient community for their continued willingness to participate in online surveys and patient studies whenever possible.



Baroness Estelle Morris
Chair of APS Support UK

During 2025, we supported a number of research organisations from the UK, and beyond, by liaising with our patient group to help produce survey results that enable the voices of people living with APS to be heard.

We remain deeply grateful to our supporters for the many and varied ways in which they raise funds and champion the work of the charity. Their generosity and commitment enable us to continue raising awareness of APS, supporting and funding research and providing vital information and guidance to those affected by the condition.

I would also like to express my sincere thanks to the APS Support UK team: Kate, Clare and Nancy whose dedication and hard work are central to everything the charity achieves.

My thanks also go to my fellow trustees for the time, knowledge and expertise they give so generously. We were delighted to welcome Ekta Fors as a trustee in 2025 and I am grateful to all trustees for their continued commitment and contribution.

We look forward to building on this year's progress and continuing to work with our supporters, researchers, healthcare professionals and the wider APS community in the year ahead.



Our Vision

A future where everyone with antiphospholipid syndrome (APS) is diagnosed early, treated appropriately and supported every step of the way.

Our Mission

APS Support UK aims to achieve earlier diagnosis and offer support to anyone affected by antiphospholipid syndrome (APS) through awareness, education and research.

Although we are a small charity, we punch well above our weight and have achieved much so far but there is much more to do. We will always do our utmost to help those affected by antiphospholipid syndrome.

Early diagnosis saves lives

Our Objectives

APS is a potentially life-threatening autoimmune disease that causes the blood to clot too quickly. The condition can cause fatal events such as strokes, heart attacks, blood clots in the lung and DVTs.

In pregnancy, APS is the most significant treatable cause of recurrent miscarriage and can increase the chance of stillbirth up to five times; it is also associated with other complications such as pre-eclampsia and premature births.

We aim to save and improve the lives of patients with antiphospholipid syndrome by achieving earlier diagnosis and the best possible treatment by:

- raising awareness of APS in the medical community
- offering information and understanding to anyone affected by APS
- funding and supporting research into APS

APS is a significantly under-recognised and under-diagnosed condition, so our charity is determined to raise the profile of APS wherever possible.

Public Benefit

The charity acknowledges its requirement to demonstrate clearly that it must have charitable purposes or 'aims' that are for the public benefit. Details of how the charity has achieved this are provided in the achievements and impact sections below. The directors confirm that they have paid due regard to the Charity Commission's guidance on public benefit before deciding which activities the charity should undertake.



Phil Godfrey, major donor and Charity Ambassador

ARE YOU AWARE OF APS?

Antiphospholipid syndrome (APS) is a life-threatening autoimmune condition that can cause strokes, heart attacks, DVTs and blood clots in the lung.

In pregnancy, APS is the most important treatable cause of recurrent miscarriage, and it is also associated with stillbirth, pre-eclampsia and premature babies.

1 IN 6 STROKES

under the age of 50 are caused by APS

1 IN 6 HEART ATTACKS

under the age of 50 are caused by APS

3 YEARS

is the average time it takes for a diagnosis of APS

34 YEARS

the average age a person is diagnosed with APS

3 MISCARRIAGES

before women are tested for APS

5 TIMES

the increased risk of stillbirth for a woman with APS

EARLY DIAGNOSIS

can prevent devastating consequences

LUPUS

is commonly associated with APS

Connect with us

@APSsupportUK

https://www.facebook.com/APSsupportUK/

APS Support UK

For people with antiphospholipid syndrome

aps-support.org.uk

0300 323 9943

Registered charity 1138116. Copyright 2018

Charity objectives achieved in 2025

Objective 1: raising awareness of APS in the medical community

International Congress on Antiphospholipid Antibodies 2025

Dr Laura Bertaloccini from the International Executive Committee for the 18th International Congress on Antiphospholipid Antibodies (ICAPA2025) requested that we provide some grant support for this important global tri-annual APS conference being held in Japan in September 2025.

As our charity believes that future APS researchers and scientists should be encouraged, we agreed and awarded grants to Dr Maria Efthymiou and Dr Christophe Lalaurie of University College London for their exceptional work. These doctors presented their findings at ICAPA in September 2025 which included the first extensive study of B2GPI using molecular dynamics.



Dr Maria Efthymiou

Thrombosis UK on-line exhibition

The charity, Thrombosis UK, approached us early in 2025 with an invitation to have a complimentary exhibition stand at their virtual exhibition for National Thrombosis Week being held in May 2025, and we accepted.

This involved setting up an APS Support UK virtual booth using the digital V-fairs platform that could be accessed by attendees at the week-long conference. The event is aimed at medical and healthcare professionals and included talks and presentations, webinars plus a scientific poster exhibition. Our booth provided lots of information about APS, links to our website and social media channels, downloadable materials such as our factsheets and newsletters plus a facility to 'chat' to us in real-time.

It was a pleasure to collaborate with Thrombosis UK at this event and we were advised afterwards that 175 people had visited our booth during the week which helped raise the profile of APS at a prestigious event.

Presentation to the Faculty of Biology, Medicine and Health at the University of Manchester

One of our volunteer ambassadors, Yvonne Wren, is an APS Expert Patient and she, once again, kindly gave a talk entitled 'A Patient Journey – Living with Autoimmunity' to the Immunology post-graduate students at the Faculty of Biology, Medicine and Health at the University of Manchester in February 2025. Yvonne's talk was very well received and she has been invited back in 2026. Her talk was filmed for the first time by the university, and we shared this (with their permission) on our You Tube channel to help reach a wider audience.

Charity objectives achieved in 2025

Objective 1: raising awareness of APS in the medical community

Royal College of Midwives online APS course

Launched in 2022, the Royal College of Midwives i-learn APS course has been freely available to all members of the Royal College of Midwives via their online platform.

We are pleased to note that, by the end of 2025, a further 18 midwives had enrolled on the course and 13 had successfully completed the i-learning module.

The RCM reported that the course continues to receive high feedback scores and evaluation from the participants; the comments are invariably constructive and include the following:

> "Really informative. Good simple update in good timeframe."

> "This explains the condition in an easy to digest way that can be reviewed to really understand the information and build knowledge."

> "As someone working with a fertility interest this has been really interesting in expanding my knowledge of APS."

> "Very informative, well-presented module which summarises all the key points really well."

Royal College of GPs online course

We have funded this course on the learning platform of the Royal College of GPs since 2017 (with continued updates from our Medical Advisers), and plan to continue to make this important online course free to access in the future.

As with most things in life, the cost of hosting the course increased in 2025 but, as we believe that this is such a valuable education tool for all healthcare professionals who want to learn about APS, we have agreed to continue funding this module to provide free access to all.

By the end of 2025 the number of healthcare professionals who have enrolled in the course since it was launched is at 2828. During 2025 there were 239 new users and 93 of these completed all parts of the course.

The average score on course pre-assessment was 48% and this rose to 82% after course completion; this 34% knowledge increase indicates how valuable the course is when teaching healthcare professionals about APS.

The overall feedback score given by participants in star ratings during 2025 was 4/5. We are, therefore, very pleased to report that this course is still proving to be a very worthwhile educational tool.

Charity objectives achieved in 2025

Objective 2: offering information and understanding to anyone affected by APS

APS Clinical Nurse Specialist

The first-ever APS Support UK funded Clinical Nurse Specialist was appointed in August 2025 after a robust recruitment process. We are delighted to be funding this unique role and trust that it will benefit the whole APS patient community in the future.

We ran a bidding process during 2024 with 9 applications being submitted and, after careful evaluation, our panel agreed to award the grant to Leeds Teaching Hospital NHS Trust. Leeds Hospital began advertising and recruiting for the APS CNS role at the start of 2025 and nurse Louise O'Prey was appointed to the role in August 2025.

Louise has previously worked as a haematology specialist nurse and has a track record of establishing and running clinics, so we feel that she is perfect for the APS CNS role. In the latter quarter of 2025, Louise had already identified and treated a number of APS patients and was busy establishing direct communication with them.

The role should last for one year until August 2026 and Louise will build her nurse-led clinics with APS patients as well as developing educational materials for patients and staff. APS Support UK is working collaboratively with Louise and she is providing us with quarterly progress reports.



Louise O'Prey,
APS Clinical Nurse Specialist

Patient support and enquiries

We do not provide specific medical advice as we would be negligent in doing so; instead, we signpost and guide patients when they contact us, so they feel supported, less isolated and confused. We aim to make them feel part of the APS community by giving reliable information, understanding and assistance whenever we can.

In 2025, we answered 36 telephone enquiries, responded to 147 emails sent directly to the charity office and to 46 messages via our social media channels. We also had 312 people sign up for our free e-newsletter and 49 people subscribed as friends of the charity.

We received some very positive feedback from the people we were in contact with, for example:

> "I'm so grateful for your continued support and words of encouragement... This has recently been a really meaningful charity for our family and will be forever grateful for the work you guys do for APS"

> "Thank you for everything you do and making me feel less alone."

> "Your information literally saved my life."

We also offer current awareness about all aspects of APS on our social medial channels including research and now operate a bespoke scheme on Instagram. The system links specific research posts to an automatic response, so when a visitor comments with the chosen keyword on a particular article, the relevant research paper link is sent directly to them via direct mail. This system is proving very popular and we had 1408 research article requests in 2025.

Charity objectives achieved in 2025

Objective 2: offering information and understanding to anyone affected by APS

Baby Loss Awareness Week campaign

We have been involved in this national awareness campaign for over 15 years and there are now over 50 other charities included, with SANDS and Tommy's Baby Charity acting as the lead charities. In 2025, the media coverage for the campaign was excellent with the Wave of Light initiative reaching global proportions and patient stories appearing in all the national media outlets including the BBC and ITVX, plus lots of local news articles.

The Baby Loss organisers asked us to create our own APS story campaign which included three brave patient volunteers and the organisers kindly shared these APS baby loss stories throughout the awareness week in October.

Baby Loss Awareness Week

APS Awareness Month

APS Support UK works in partnership with other national patient organisations to raise awareness of APS annually during the month of June. We do this by creating and encouraging others to share our daily infographics via our social media channels; the infographics focus on 30 specific topics relating to APS and its symptoms. 2025 was a successful year and we had a very busy time on the social media channels during June connecting with, and supporting, our patient group.

APS Specialists Directory on our website

In 2025, we have received a lot of interest in the free online APS Specialist Directory we host on our website and it, increasingly appears, that our register is now accessed by both patients and doctors. In light of this, we conducted a thorough review of the doctors included in the directory throughout 2025 to make sure it is up-to-date; we also appealed to our patient community to recommend any new APS specialists then wrote to those doctors to ask if they would like to be included in the directory. We now have 119 doctors in the APS specialists directory and believe this unique resource is a valuable tool that helps support APS patients.

Life Insurance for people with APS

We continued to partner with Cura Insurance throughout 2025 with the aim of helping people with APS potentially obtain life insurance policies. Cura Insurance is a company specialising in pre-existing medical conditions and understands the difficulty that many people with APS face when trying to take out life insurance policies. APS is an unknown risk in the insurance world which can preclude patients from being offered cover which can have a detrimental effect on their chances of taking out mortgages and life assurance.

As with previous years, to try and support our community by reaching the largest audience possible, we promoted our webpage with a QR code on our social media platforms and also sent direct e-shots and included articles in our hard copy newsletters to those who wish to receive information in this format.

cura

Charity objectives achieved in 2025

Objective 3: funding and supporting research into APS

APS Support UK Research Fund

Our APS Research Fund is now in its seventh year and, as the charity is very financially stable following another legacy, we decided to increase the grant awards available to applicants from £10,000 in 2024 up to £20,000 in 2025.

We were hoping that this would increase the number of applicants, and it certainly had the desired effect as we received the most applications in the history of the APS Research Fund with 7 scientists and groups applying. Most research teams were London-based but, almost all applications included collaboration with other groups from a wide range of places including Birmingham, Bath, Australia, Peru and Denmark.

After a rigorous and robust peer-review panel process which included two new external reviewers, we awarded 5 grants for the 2025 funding round as follows:

- Dr Deepa J Arachchillage, Dr Catherine Ducker, Dr Charis Pericleous of the Department of Immunology and Inflammation at Imperial College London were awarded a grant to work on the project: 'MicroRNA signature in APS patients with Recurrent Thrombosis, compared to single event and asymptomatic aPL carriers'.

Grant award: £19,439



- Dr Thomas McDonnell (above), Associate Professor of Biomarker Discovery of University College London was awarded a grant to work on a project looking at 'Adolescent APS: Redressing the Imbalance'.

Grant award: £19,500

- Clinical Nurse Specialist Louise O'Prey from Leeds Teaching Hospitals Trust was awarded funding to support the project 'Improving APS Patient Care Through Research on Point-of-Care Self-Testing at Leeds Hospital Trust'.

Grant award: £10,800

- Dr Muhammad Shipa, Academic and Experimental Rheumatologist, Division of Medicine, University College London was awarded a grant for the project: 'Isotype-Driven Innate Activation by Anti-β2GPI-Domain I Antibodies in APS: Mechanistic Biomarkers for Risk Stratification'.

Grant award: £19,965

- Dr Maria Efthymiou (above), Dr Ibrahim Tohidi-Esfahani and Professor Hannah Cohen from the Department of Haematology, University College of London were awarded a grant for the project: "Complement mediated platelet and tissue factor associated hypercoagulability for risk stratification of patients with antiphospholipid syndrome associated with acute ischemic stroke: a novel therapeutic target?'.

Grant award: £19,658

We were delighted to be able to invest in these projects which should have an immense impact on the future of APS research, and look forward to seeing the outcome of these research investigations in due course.

In addition to awarding grant funding for research projects, we also awarded two doctors with £1,000 travel grants so they could present their work at the International Congress of Antiphospholipid Antibodies 2025 held in Kyoto, Japan.

Charity objectives achieved in 2025

Objective 3: funding and supporting research into APS

European Reference Network for Rare and Complex Connective Tissue and Musculoskeletal Disease Team (ReCONNET)

In April 2025, ERN ReCONNET (the European Reference Network for Rare and Complex Connective Tissue and Musculoskeletal Disease Team) invited us to share a survey with the aim of collecting the experiences of patients' living with rare and low prevalence connective tissue diseases. Patients were asked to submit their own stories directly to ERN ReCONNET and discuss their disease and care pathways.

ERN ReCONNNET hope that by better understanding patients' lived-experiences, they will be able to integrate the perspective of patients to create an ideal pathway with the aim of harmonising care in Europe. Our patient group was very responsive to ERN ReCONNET's survey which we shared via e-mail and social media and we were happy to collaborate with this well-known rare disease group.

Guy's & St Thomas' Hospital Trust (GSTT) Patient & Public involvement for thrombophilia testing study

In May 2025, Dr Andrew Doyle, a consultant haematologist from GSTT, asked us if we were able to provide support for Patient & Public Involvement (PPI) for a potential study looking at thrombophilia testing after unprovoked venous thromboembolism (VTE).

He was ideally looking for expert patients that may be able to support a potential study steering committee and/or advise on initial study design. We did an appeal in our newsletter and received 9 candidates who were able to share their stories with Dr Doyle.

University of Cambridge: INSPIRE project

In May 2025, we received a request from the Cambridge University's INSPIRE project asking us to help recruit APS patients for a survey study entitled INSPIRE-Flare: Investigating flare triggers, preventers and prodromes in autoimmune disease patients. This study aimed to improve understanding of triggers, preventers and the progression of symptoms in autoimmune disease flares in order to improve recognition and treatment. Our APS patient group, as ever, responded very well on our social media channels.

University of Cambridge: Long-Term Conditions Group, Department of Public Health & Primary Care

In January 2025, Kaira Kuhu Naidu MSC from the Long-Term Conditions Group, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge asked us to share surveys for patients and clinicians on the impact of autoimmune diseases on health and quality of life, with a special emphasis on APS. We shared this with our patient and professionals groups directly via email and there were over 600 APS respondents in the final survey.

Charity objectives achieved in 2025

Objective 3: funding and supporting research into APS

National Institute for Health and Research: project SAMuel

In July 2025, we were invited to share a project organised by the University of Exeter as part of the National Institute for Health and Care Research (NIHR) Patient and Public Involvement team supporting the involvement of stroke survivors (and carers of stroke survivors) in an NIHR-funded project called SAMueL.

SAMueL stands for Stroke Audit Machine Learning. It is a project that uses Artificial Intelligence (AI) and Machine Learning (ML) models to improve thrombolysis rates by recreating the various steps of the stroke pathway at any given hospital. The model can then be used to predict if thrombolysis would be used more often if we, for example, reduced the time it took to be scanned after arrival. The organisers wanted our patient group to share their thoughts and comments about their experiences and the APS community was, again, happy to be involved.

John Hopkins University (USA) study

In October 2025, we received a request from Dr Shruti Chaturvedi, haematologist and researcher at John Hopkins University, Baltimore, US asking if we would be willing to disseminate a survey. The survey aimed to collect anonymous information on patients' APS diagnosis and its impact through a standardized quality of life tool (PROMIS29). This study has been approved by the institutional review board/ ethics board at Johns Hopkins University so we were happy to share it with our patient group via our social media channels.

Our Impact in 2025

Will Elliot ran the 2025
Northstowe Running Festival



Our Impact in 2025

Website

Throughout 2025, the APS Support UK website continued to provide accessible, reliable information to people affected by APS in the UK and around the world.

Visitors engaged more deeply with the website this year, with the number of pages viewed per user increasing by 10.5% and the average engagement time rising by 8.9% to 2 minutes 15 seconds.

Our visitors seem very pleased with the content and reliability of the information on our website and we were pleased to receive the following comment this year:

> "Your website has been the best learning tool ever; it's the only place in the world that I have learned so much about APS since I've had it. I have got to sing your praises to everyone as it is the best source of information ever."

Our APS symptom webpages continued to attract significant interest. Visitors spent longer engaging with several key resources, including information about APS symptoms, pregnancy, bones and joints. There was a lot more interest in the 'What causes APS' information this year, with the average engagement time spent on this webpage increasing by more than 33%.

55,000 active users

The website continued to reach an international audience, with more than 30,000 active users in the UK and 25,000 in the United States. We also saw encouraging growth in Ireland, where active users increased by almost 88%, as well as increased use from Germany.

65.3% mobile users

Mobile phone remained the most common way to access our website, accounting for 65.3% of users, highlighting the importance of ensuring our APS information remains easy to access wherever people need it.

Our Impact in 2025

Social Media

Our social media channels continued to play an important role in raising awareness of APS and helping people find reliable information and support throughout 2025.

On Facebook, our content received 2.2 million views, while people interacted with our posts 30,600 times, an increase of 189.5% compared with the previous year. Our Facebook page received 54,200 visits, up 262.4%, while link clicks increased by 60.1% to 5,900. We also recorded 1,700 new follows, an increase of 43.7%.

Our Instagram account also saw significant growth during the year, reaching 62,000 accounts, with Meta reporting an increase of 443.5% compared with 2024. Our content received more than 250,000 views and 5,700 interactions, while profile visits rose to 5,600. We also welcomed 162 new followers during the year.

2.2 million views

1,700 new followers


an increase of 43.7%

62k reach,

an increase of

443.5%

These figures reflect the growing reach of APS Support UK's digital content and the important role social media continues to play in connecting people affected by APS with accessible, evidence-based information and support.*




** Year-on-year percentage changes are those reported directly by Meta Business Suite for 1 January–31 December 2025 compared with the equivalent 2024 period. Meta's current historical reporting may differ from figures previously recorded in APS Support UK's 2024 annual report.*

Our Impact in 2025

Supporting patients through charitable activities

To ensure that the charity's resources are spent wisely, our two employees record and log the time spent on charitable activities, and the results for 2025 are shown below:



Our Impact in 2025

APS in the news 2025

There were lots of stories in the local press and online platforms involving patients and their families who bravely shared their APS experiences throughout 2025. The following articles all helped raise awareness of APS in the general public:

January 2025

Danny Lloyd, one of our long term supporters and patient stories on our website appeared in the Bristol World newspaper helping raise awareness of his horrific catastrophic APS experience and extraordinary recovery story:

https://www.bristolworld.com/community/blood-pressure-check-could-save-your-life-says-bristol-stroke-survivor-4966521

April 2025

Lauren Connelly and Jed Hodges described their rollercoaster APS baby journey in the Central Fife Times following the birth of little Jude:

https://www.centralfifetimes.com/news/25070590.lochore-mum-fundraising-thank-hospital-saved-baby/

The Evening Standard published an article about Meghan Markle's experience with pre-eclampsia and it listed APS as one of the main conditions that increase the chances of developing pre-eclampsia:

https://www.standard.co.uk/lifestyle/wellness/what-is-preeclampsia-meghan-markle-postpartum-b1221353.html

July 2025

The Independent published an article about the health benefits of ginger and mentioned APS when discussing its anti-inflammatory benefits:

https://www.independent.co.uk/life-style/health-and-families/ginger-benefits-cholesterol-heart-health-b2813969.html

August 2025

The BBC reported on a Coroners' Prevention of Future Deaths report when an APS patient died in hospital due to "delays in recognising and appropriately treating" her condition:

https://www.bbc.co.uk/news/articles/c6203j2edkwo

Our Impact in 2025

Collaboration

As we are a small charity, our impact is increased through collaboration with other charities, campaigns and organisations. We are grateful for the following organisations' generosity in sharing information and working with us during 2025:

- APS ACTION
- APS Foundation of America
- APS Foundation of Australia
- Baby Loss Awareness Week
- The British Society of Haematology
- Cura Life Insurance
- Different Strokes
- Eat on warfarin
- European Reference Network for Rare and Complex Connective Tissue and MKS Diseases
- EURORDIS – Rare Diseases Europe
- Leeds Teaching Hospitals NHS Trust
- LUPUS UK
- Mama Academy
- Manchester University Faculty of Biology, Medicine and Health
- Michigan University Medical School
- National Institute for Health and Care Research (NIHR) Patient and Public Involvement
- Prescription Charges Coalition
- RAIRDA – the Rare Autoimmune Rheumatic Disease Alliance
- Rosetrees Trust
- Royal College of GPs
- Royal College of Midwives
- Spanish APS Association
- Thrombosis UK
- Tommy's Baby Charity
- World Thrombosis Day

Volunteers

We are very fortunate to have two world-leading APS experts as our Medical Vice-Chairs who write all our medical material, update the GP and midwife online course modules, help with complex enquiries and can contact their peers, if necessary, on specific APS subjects such as reviewing grant applications for our APS Research Fund.

APS Support UK expanded the skillset on our board in 2025 by welcoming Ekta Fors as a trustee. Ekta has over 20-years' experience in investment banking with a mix of governance and policy roles which will be a tremendous help for the charity as we look to strengthen our governance, policies and procedures in 2026.

We are extremely grateful to our charity ambassadors who give personal talks around the country to help raise awareness of APS, particularly Phil Godfrey, who continues to give talks to Rotary Clubs throughout the UK to raise awareness of APS. Phil continues to be a major fundraiser for our charity, and we are very grateful for his continued support and incredible efforts on behalf of APS patients in memory of his wife, Christine.

Another one of our volunteer ambassadors, Yvonne Wren, is an Expert Patient, and she regularly presents her talk 'A Patient Journey – Living with Autoimmunity' to post-graduate students whenever possible.

We are also very grateful to all the wonderful volunteers who agreed to share their APS experiences on the Patient Stories section of our website: https://aps-support.org.uk/self-help/patient-stories and those who shared their Baby Loss stories for release in Baby Loss Awareness Month 2025.



Phil Godfrey our charity ambassador works in memory of his wife, Christine



Expert Patient Yvonne Wren

Future plans for 2026

Thrombosis UK Awareness Week online booth

As our participation at the Thrombosis UK event this year was so successful, we are hoping that we will be invited to set up another online booth in the Thrombosis UK Awareness Week 2026. We believe this is an excellent way to raise awareness of APS to both professionals and patients as this is a well-known and prestigious event.

APS Clinical Nurse Specialist

We were delighted to establish our first-ever APS CNS at Leeds Hospital in August 2025 and have received the first quarterly report by the nurse, Louise O'Prey. This report is very encouraging with Louise taking our online APS healthcare module and passed with 100% and we look forward to working with her throughout 2026.

Louise is aiming to further develop APS patient clinics and materials and we are hopeful that Leeds Hospital will choose to extend her role past the 1-year term being funded by us.

PhD Studentship

We have been exploring whether it would be possible to co-fund a 3-year PhD Studentship in the field of APS with the Rosetrees Trust. Our vice Medical Chair Professor, Anisur Rahman, has been in discussions with the trust this year as the Rosetrees are open to the idea and have agreed to co-fund a PhD studentship with our charity. We will help promote the APS funding round in 2026 via our professionals network and communications channels and hope that a successful candidate and project is found in 2026.

Charity policies

A new trustee, Ekta Fors, joined our board at the end of 2025 and we are aiming to strengthen our charity's governance through new policies and procedures with Ekta's support throughout 2026.

Legal and Administrative Information

The Trustees present their final report and the unaudited financial statements for the year ended 31 December 2025.

The legal and administrative information set out below forms part of this report. The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, the requirements of the Charities Act 2011, the Charities SORP (FRS 102) and the Companies Act 2006.

Registered Company Number:	07268671
Registered Charity Number:	1138116
Date of Incorporation:	2010
Working name:	APS Support UK
Financial Year:	1st January 2025 - 31st December 2025
Principal / registered address:	The Orchard White Hart Lane Basingstoke Hampshire RG21 4AF
Directors / Trustees and to date:	Baroness Morris of Yardley (Chair) **during the year** Dr John Wolffe Professor David D'Cruz Professor Anisur Rahman Mr James Turner Mr Christopher Mansbridge Ms Ekta Fors (appointed 12 November 2025)
Bankers:	NatWest Lambeth North Branch 91 Westminster Bridge Road London SE1 7ZB
Independent Examiners:	Knight Goodhead Limited 7 Bournemouth Road, Chandler's Ford, Eastleigh, Hampshire, S053 3DA

Governance and Management

Governing Document

The charity operates under a Memorandum and Articles of Association.

Appointment, retirement and training of the Trustees

When a vacancy occurs on the Board of Trustees, the board will take the opportunity to review the skill sets of trustees to identify specific abilities that would strengthen the Board's overall effectiveness. New trustees are recruited via our communication channels or professional organisations such as Reach Volunteering.

Governance of the Charity

The Board of Trustees meets three times a year to provide strategic direction and areas of activity for the charity.

Day-to-day operations and administration are delegated to the Management Team to provide regular reports to the trustees on performance and operations.

Risk Assessment

The trustees review the major risks which the charity faces and believe that by maintaining the free reserves stated, combined with the annual review of the controls over key financial systems carried out on an annual basis, the charity will provide sufficient resources in the event of adverse conditions.

The trustees have also examined the other operational and business risks that they face and consider the systems in place for the day-to-day operation of APS Support UK to be appropriate to our current size. Still, they are aware that as, and when, the charity grows, we will need to develop and implement procedures and reporting regimes to mitigate the risks associated with running a charitable company.

Financial Review

Statement of responsibilities of the trustees

The trustees are responsible for preparing the annual report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (UK GAAP).

The trustees are required to prepare the annual report and financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including income and expenditure, for the period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the charity will continue operation.

The trustees are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies, and complies with the charity's governing document and The Statement of Recommended Practice: Accounting and Reporting by Charities using FRS 102.

Results for the Year

For the financial year ended 31 December 2025, the charity made a surplus of £2,644 (2024: £18,699). Income totalled £160,918 (2024: £114,900), with expenditure of £158,274 (2024: £96,201).

Total funds at 31 December 2025 are £401,151 (2024: £398,507), of which £232,416 (2024: £203,000) relate to designated funds, with £29,071 (2024: £40,214) relating to restricted funds.

£73,000 of designated funds (2024: £73,000) relate to the designated reserve explained in the reserve policy. General funds total £139,664 (2024: £155,293). The trustees continue to keep the level of reserves under close review to ensure the needs of the charity can be met.

Reserves Policy

The trustees decided to introduce a designated reserve in the annual accounts for 2017 onwards. The reserve will protect the charity from the risk of unforeseen emergencies or other unexpected need for funds and illustrates to trustees, donors, creditors, employees, beneficiaries and others that the charity is adequately financially equipped to meet its existing and planned commitments and obligations.

Independent examiner's report to the trustees on the unaudited accounts of Hughes Syndrome Foundation

I report to the charity trustees on my examination of the accounts of the company for the year ended 31 December 2025, which are set out on pages 25 to 35.

Responsibilities and basis of report

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (the "2006 Act").

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 (the '2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's report

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those accounting records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective October 2019).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

J E Harris FCCA
Knight Goodhead Limited
Chartered Accountants
7 Bournemouth Road
Chandler's Ford, Eastleigh
Hampshire SO53 3DA

Statement

Financial Activities for the year ended 31st December 2025

Including Income and Expenditure Account

INCOMING RESOURCES

	Notes	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Donations and legacies		£102,493	£2,483	£104,976	£74,369
Charitable activities		£46,593	£200	£46,793	£33,420
Investment income		£9,049	-	£9,049	£7,090
Other income		-	£100	£100	£21
TOTAL INCOME	**3**	**£158,135**	**£2,783**	**£160,918**	**£114,900**

EXPENDITURE

	Notes	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Raising funds		£4,267	-	£4,267	£4,110
Charitable activities		£140,081	£13,926	£154,007	£92,091
TOTAL EXPENDITURE	**4**	**£144,348**	**£13,926**	**£158,274**	**£96,201**

NET INCOME / (EXPENDITURE) FOR THE PERIOD

	Notes	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
TOTAL NET INCOME		**£13,787**	**(£11,143)**	**£2,644**	**£18,699**

FUNDS

	Notes	Unrestricted Funds	Restricted Funds	2025 TOTAL	2026 TOTAL
Funds at 1 January 2025		£358,293	£40,214	£398,507	£379,808
FUNDS AT 31 December 2025	**10**	**£372,080**	**£29,071**	**£401,151**	**£398,507**

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 8 to the financial statements.

Comparative statement of financial activites year ended 31 December 2024

Including Income and Expenditure Account

INCOME

	Notes	Unrestricted Funds	Restricted Funds	2024 Total
Donations and legacies		£63,455	£10,914	£74,369
Charitable activities		£32,800	£620	£33,420
Investment income		£7,090	-	£7,090
Other income		£21	-	£21
TOTAL INCOME	**3**	**£103,366**	**£11,534**	**£114,900**

EXPENDITURE

	Notes	Unrestricted Funds	Restricted Funds	2024 Total
Raising funds		£4,110	-	£4,110
Charitable activities		£76,015	£16,076	£92,091
TOTAL EXPENDITURE	**4**	**£80,125**	**£16,076**	**£96,201**

NET INCOME / EXPENDITURE FOR THE PERIOD

	Notes	Unrestricted Funds	Restricted Funds	2024 Total
NET INCOME / EXPENDITURE FOR THE PERIOD		**£23,241**	**(£4,542)**	**£18,699**

FUNDS

	Notes	Unrestricted Funds	Restricted Funds	2024 Total
Funds at 1 January 2024		£335,052	£44,756	£379,808
FUNDS AT 31 December 2024	**10**	**£358,293**	**£40,214**	**£398,507**

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above.

Balance sheet as at 31 December 2025

CURRENT ASSETS

	Notes	2025		2024	
Debtors	6	£48,277		£7,634	
Cash at bank and in hand	**7**	£405,669		£403,728	
		£453,946		**£411,362**	

CREDITORS

	Notes	2025		2024	
Amounts falling due within one year Accruals		(£52,795)		(£12,855)	
NET ASSETS	**10**		**£401,151**		**£398,507**

FUNDS

	Notes	2025		2024	
Restricted funds	**8**		£29,071		£40,214
Unrestricted funds			-		-
General funds	**8**		£139,664		£155,293
Designated funds	**8**		£232,416		£203,000
TOTAL FUNDS			**£401,151**		**£398,507**

For the financial period ended 31 December 2025, the company was entitled to exemption from audit under section 477 Companies Act 2006; and no notice has been deposited under section 476. The directors acknowledge their responsibilities for ensuring that the company keeps accounting records, which comply with section 386, and preparing accounts, which give a true and fair view of the state of affairs of the company as at the end of the year and of its income and expenditure for the financial year, in accordance with the requirements of section 394 and 395, and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the board of trustees on 22/09/26 and signed on its behalf by:

James Turner
Trustee

Notes to the accounts for the year ended 31 December 2025

1. ACCOUNTING POLICIES

a) Accounting convention

The financial statements have been prepared in accordance with the Financial Reporting Standardapplicable in the UK and Republic of Ireland (FRS 102) and the Accounting and Reporting by Charities:

Statement of Recommended Practice applicable to charities preparing their accounts in accordance with FRS 102 (effective 1 January 2019), and the Companies Act 2006.

The charity meets the definition of the public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

The accounts have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue.

b) Income

Income is recognised in the statement of financial activities in the year in which it is receivable.

Grants and donations are only included in the statement of financial activities when the charity has unconditional entitlement to the resources.

Income from tax reclaims are included in the statement of financial activities at the same time as the gift.

Legacies are recognised when the charity is notified of its legal entitlement and the amount due can be reliably estimated.

Investment income is included in the accounts when receivable.

c) Expenditure

Expenditure is recognised in the period in which they are incurred. Research grants are recognised when the grants are agreed. Resources expended include attributable VAT which cannot be recovered.

d) Fund accounting

Funds held by the charity are either:

Unrestricted general funds

Funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated funds

Funds which are set aside for specific purposes by the trustees to be used in accordance with the charitable objects.

Restricted funds

Funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purpose.

e) Tangible fixed assets

Fixed assets are capitalised where the purchase price exceeds £1,000. Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life.

2. LEGAL STATUS

The charity is a company limited by guarantee and has no share capital. The charitable company was incorporated on 1 June 2010 in England and Wales and was registered on 17 September 2010 with the Charity Commission in England and Wales. The charity is a public benefit entity.

The registered office of the charitable company is The Orchard, White Hart Lane, Basingstoke, Hampshire, RG21 4AF.

Notes to the accounts for the year ended 31 December 2025

3. INCOME

Donations & Legacies	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Donations	£39,774	£2,483	£42,257	£52,235
Legacies	£52,000	-	£52,000	£3,000
Gift aid recoverable	£10,719	-	£10,719	£19,134
TOTAL	**£102,493**	**£2,483**	**£104,976**	**£74,369**

Charitable activities	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Fundraising income	£35,135	£200	£35,335	£22,049
Membership renewals	£11,458	-	£11,458	£11,371
TOTAL	**£46,593**	**£200**	**£46,793**	**£33,420**

Investment Income	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Bank Interest	£9,049	-	£9,049	£7,090
TOTAL	**£9,049**	**-**	**£9,049**	**£7,090**

Other Income	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Sundry Income	-	£100	£100	£21
TOTAL	**-**	**£100**	**£100**	**£21**

	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
TOTAL INCOME	**£158,135**	**£2,783**	**£160,918**	**£114,900**

Included within legacies is £42,000 of accrued legacy income received in May 2026.

Notes to the accounts for the year ended 31 December 2025

4. EXPENDITURE

Raising funds	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Fundraising costs	£4,267	-	£4,267	£4,110
TOTAL	**£4,267**	**-**	**£4,267**	**£4,110**

Charitable activities	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
Staff costs	£60,898	-	£60,898	£54,660
Insurance costs	£469	-	£469	£446
Office costs	£2,364	-	£2,364	£2,360
Raising awareness	£11,585	-	£11,585	£12,639
Rent	£4,206	-	£4,206	£4,104
Legal and professional fees	£454	-	£454	£368
Accountancy	£1,639	-	£1,639	£1,438
Grants paid	£45,839	£9,000	£54,839	£11,000
APS Clinical Nurse Specialist Project	£12,584	£4,924	£17,508	£5,076
Bank charges	£43	£2	£45	-
TOTAL	**£140,081**	**£13,926**	**£154,007**	**£92,091**

	Unrestricted Funds	Restricted Funds	2025 TOTAL	2024 TOTAL
TOTAL EXPENDITURE	**£144,348**	**£13,926**	**£158,274**	**£96,201**

The independent examination fee included in accountancy amounted to £1,579 (2024: £1,438).

Grants of £nil (2024: £nil) were paid as part of the Louise Gergel Fellowship Project.

Grants of £nil (2024: £10,000) were payable to University College London.

Grants of £3,000 (2024: £nil) were payable to The Royal College of GP's.

Grants of £17,508 (2024: £nil) were paid to The Leeds Teaching Hospital NHS Trust as part of the APS Nurse Specialist Project.

Notes to the financial statements for the year ended 31st December 2025

5. EMPLOYED STAFF COSTS AND NUMBERS

	2025	2024
Salaries and wages	£58,818	£53,068
Social security costs	£315	-
Pension	£1,765	£1,592
TOTAL	**£60,898**	**£54,660**

No employee earned more than £60,000 during this or the prior period.
The total number of employees during the period was 2 (2024: 2).

Key management were paid remuneration totalling £48,310 (2024: £46,792).

No trustee received any remuneration during this or the prior period.

Trustees' indemnity insurance of £44 (2024: £34) for the Board of Trustees was paid during the year.

6. DEBTORS

	2025	2024
Gift aid recoverable	£5,000	£6,253
Prepayments and accrued income	£1,277	£1,381
Legacy vested but not yet distributed (estimate)	£42,000	-
TOTAL	£48,277	**£7,634**

7. CASH AT BANK AND IN HAND

Bank balances are held as follows:

	2025	2024
NatWest current account	£19,410	£78,425
NatWest deposit account	£52,247	£50,172
Shawbrook bank	£84,481	£81,790
Cambridge and Counties	£92,536	£89,003
Earl Shilton	£83,476	£80,803
Saffron Building Society	£51,269	-
Louise Gergel account	£21,244	£21,003
PayPal	£1,006	£2,532
TOTAL	**£405,669**	**£403,728**

Notes to the accounts for the year ended 31 December 2025

8. MOVEMENT IN FUNDS

Restricted funds	At 1 January 2025	Income	Expenditure	Transfers	At 31 December 2025
Louise Gergel Fellowship	£21,003	£243	(£2)	-	£21,244
APS Projects Fund	£5,287	£2,540	-	-	£7,827
APS Research Fund	£9,000	-	(£9,000)	-	-
APS Clinical Nurse Specialist Project	£4,924	-	(£4,924)	-	-
TOTAL	**£40,214**	**£2,783**	**(£13,926)**	**-**	**£29,071**

Designated funds	At 1 January 2025	Income	Expenditure	Transfers	At 31 December 2025
APS Projects fund	£20,000	-	-	-	£20,000
Designated reserve fund	£73,000	-	-	-	£73,000
APS Clinical Nurse Specialist Project	£60,000	-	(£12,584)	-	£47,416
PhD Studentship Grants Award	£50,000	-	-	-	£50,000
Legacy fund	-	£42,000	-	-	£42,000
TOTAL	**£203,000**	**£42,000**	**(£12,584)**	**-**	**£232,416**

Unrestricted funds	At 1 January 2025	Income	Expenditure	Transfers	At 31 December 2025
General funds	**£155,293**	**£116,135**	**(£131,704)**	**-**	**£139,664**

	At 1 January 2025	Income	Expenditure	Transfers	At 31 December 2025
TOTAL FUNDS	**£398,507**	**£118,918**	**(£158,274)**	**-**	**£401,151**

Notes to the accounts for the year ended 31 December 2025

8. MOVEMENT IN FUNDS - PRIOR YEAR FUNDS MOVEMENTS

Restricted funds	At 1 January 2024	Income	Expenditure	Transfers	At 31 December 2024
Louise Gergel Fellowship	£20,649	£354	-	-	£21,003
APS Projects Fund	£15,107	£1,180	(£11,000)	-	£5,287
APS Research Fund	£9,000	-	-	-	£9,000
APS Clinical Nurse Specialist Project	-	£10,000	(£5,076)	-	£4,924
TOTAL	**£44,756**	**£11,534**	**(£16,076)**	**-**	**£40,214**

Designated funds	At 1 January 2024	Income	Expenditure	Transfers	At 31 December 2024
APS Projects fund	£20,000	-	-	-	£20,000
Designated reserve fund	£73,000	-	-	-	£73,000
APS Clinical Nurse Specialist Project	-	-	-	£60,000	£60,000
PhD Studentship Grants Award	-	-	-	£50,000	£50,000
TOTAL	**£93,000**	**-**	**-**	**£110,000**	**£203,000**

Unrestricted funds	At 1 January 2024	Income	Expenditure	Transfers	At 31 December 2024
General funds	**£242,052**	**£103,366**	**(£80,125)**	**(£110,000)**	**£155,293**

	At 1 January 2024	Income	Expenditure	Transfers	At 31 December 2024
TOTAL FUNDS	**£379,808**	**£114,900**	**(£96,201)**	**-**	**£398,507**

Notes to the accounts for the year ended 31 December 2025

8. MOVEMENT IN FUNDS

RESTRICTED FUNDS

Louise Gergel Fellowship
The Louise Gergel Fellowship is a dedicated family memorial fundraising sub-committee who raise funds for medical research and bursaries only.

Research and Projects Fund
This fund is for specific projects organised by the charity, such as our online APS courses for healthcare staff and patient initiatives such as patients days and conferences.

APS Research Fund
The 'APS Research Fund' was the fund launched in 2019 for researchers to apply to for grant funding for their work, with individuals able to apply for up to a maximum of £20,000 each.

APS Clinical Nurse Specialist Project
The APS Clinical Nurse Specialist role is being set up with the aim of creating a service within an NHS clinic to provide support and advice specifically for patients with APS; for example on subjects like symptom control, anticoagulation and vaccinations.

DESIGNATED FUNDS

Designated Reserve Fund
This reserve protects the charity from the risk of unforeseen emergency or other unexpected need of funds and illustrates to Trustees, Donors, Creditors, Employees, Beneficiaries and others that the charity is adequately financially equipped to meet its existing and planned commitments and obligations.

Research and Projects Fund
The Research and Projects Fund is for medical research and specific projects such as online APS courses for healthcare staff and patient initiative such as conferences etc.

APS Clinical Nurse Specialist Project
The Clinical Nurse Specialist fund is for payment of the salary and associated costs for the new APS Clinical Nurse Specialist role which we are funding at Leeds Hospital NHS Trust for one year from August 2025 until August 2026.

PhD Studentship Grants Award
The Rosetrees PhD Reserve fund is for our contribution to the PhD Studentship in the area of APS being jointly funded by APS Support UK and the Rosetrees Trust across 3 years, planned to commence in 2025.

Legacy Fund
We were heartened to receive notification in 2025 of a Legacy vested in our favour of approximately £42,000. The Legacy amount of £42,469.21 was received on 20 May, 2026.

Notes to the accounts for the year ended 31 December 2025

9. RELATED PARTY TRANSACTIONS

During this year and the prior year, no trustees were reimbursed expenses incurred on behalf of the charity.

10. ANALYSIS OF NET ASSETS BETWEEN FUNDS

2025	Restricted funds	Designated funds	Unrestricted funds	2025 Total funds
Current assets	£29,071	£232,416	£192,459	£453,946
Current liabilities	-	-	(£52,795)	(£52,795)
NET ASSETS	**£29,071**	**£232,416**	**£139,664**	**£401,151**

2024	Restricted funds	Designated funds	Unrestricted funds	2024 Total funds
Current assets	£40,214	£203,000	£168,148	£411,362
Current liabilities	-	-	(£12,855)	(£12,855)
NET ASSETS	**£40,214**	**£203,000**	**£153,293**	**£398,507**